Akebia Therapeutics Conference Call Summary Company Overview - **Company**: Akebia Therapeutics (NasdaqCM:AKBA) - **Focus**: Development of therapies for kidney disease, particularly anemia in chronic kidney disease patients Key Strategic Areas 1. **Commercial Product - Vafseo**: - Aim to establish Vafseo as the standard of care for anemia in chronic kidney disease patients on dialysis [3][7] - Ongoing phase four and three B trials to generate necessary data for standardization [3] 2. **Commitment to Kidney Disease**: - Focus on expanding the pipeline related to kidney disease, including drugs like praliciguat and AKB-907 [3][4] 3. **Future Beyond Kidney Disease**: - Small investments in other areas such as aducanumab and retinopathy of prematurity [4] Vafseo Product Insights - **Mechanism**: Vafseo is a HIF-PH inhibitor that offers a new approach to managing anemia, with fewer dose titrations and easier administration for physicians [7][8] - **Clinical Data**: - Phase 3 study showed a statistically significant reduction in mortality and hospitalization rates [8] - An 8% decrease in hospitalization and a 15% cost reduction per patient per year, translating to approximately $3.7 billion savings if all eligible patients switched from ESAs to Vafseo [9][10] - **Market Potential**: - Post-TDAPA market opportunity estimated at $1 billion, with potential for Vafseo to be a $500 million product [26][30] Dosing Strategy - **TIW Dosing**: - Transitioning to TIW (three times a week) dosing to improve patient adherence and ease of use for nephrologists [12][14] - Ongoing studies (VOICE and VOCAL) to validate TIW dosing effectiveness [15][37] Pipeline Developments 1. **Praliciguat**: - Targeting focal segmental glomerulosclerosis (FSGS) with a unique mechanism of action [49][50] - Phase 2 trials initiated, with a focus on demonstrating efficacy in a high unmet need area [50] 2. **AKB-097**: - A complement inhibitor with a tissue-targeted effect, expected to have a better safety profile and dosing regimen compared to existing treatments [51][52] - Basket study planned for multiple indications, including IgAN and lupus nephritis, with data expected in 2027 [53][54] Financial Metrics and Market Perception - **Investor Metrics**: - Focus on increasing the number of prescribers and adherence rates for Vafseo [60] - Balanced capital allocation to support both Vafseo and the pipeline [61] - **Market Understanding**: - Complexity of dialysis reimbursement may lead to underappreciation of Akebia's market potential [62] - Emphasis on the importance of consistent revenue growth and pipeline visibility to attract investor confidence [63][64] Conclusion - Akebia Therapeutics is positioned to leverage its innovative product Vafseo and a robust pipeline to address significant unmet needs in kidney disease, with a clear strategy for market penetration and growth potential in a billion-dollar market.

CorMedix FY Conference Summary Company Overview - **Company**: CorMedix (NasdaqGM:CRMD) - **Industry**: Specialty Pharmaceuticals - **Focus**: Institutional settings of care, primarily injectable drugs used in hospitals and infusion centers [2][3] Financial Highlights - **Cash Position**: Approximately $150 million cash on hand, close to zero net debt [2][6] - **Revenue Guidance for 2026**: Expected to exceed $300 million, with EBITDA between $100-$125 million [3][5] - **2025 Revenue**: Exceeded $400 million, driven by DefendCath and Melinta acquisition [5][6] Key Products and Pipeline DefendCath - **Approval**: Approved in late 2023, launched mid-2024 [6][8] - **Indication**: Reduces risk of catheter-related bloodstream infections (CRBSIs) in hemodialysis patients [8][9] - **Market Size**: Total addressable market (TAM) of approximately $750 million [23] - **Reimbursement**: Under CMS's TDAPA, transitioning to post-TDAPA add-on period in July 2026 [10][11] - **Clinical Impact**: Phase 3 study showed a 71% reduction in CRBSI risk; real-world data from US Renal Care showed a 70% reduction in hospitalizations [12][13] Rezzayo - **Current Status**: In phase three clinical studies for prophylaxis of fungal infections in immunocompromised patients, with results expected in Q2 2026 [3][14] - **Market Potential**: TAM over $2 billion for prophylaxis of invasive fungal infections [21] Leadership and Team - **New Additions**: Mike Seckler as Chief Commercial Officer and Susan Blum as CFO, enhancing the leadership team [4] Strategic Initiatives - **Acquisition of Melinta**: Added $140 million in revenue and a portfolio of anti-infectious products [5][16] - **Future Growth**: Focus on expanding indications for existing products and pursuing strategic tuck-in business development [17][23] Market Position and Valuation - **Current Valuation**: Trading at a significant discount compared to peers (5x EBITDA vs. 12x for peers) [27] - **Investor Education**: Emphasis on improving communication regarding the value of Rezzayo and DefendCath for TPN [27][28] Upcoming Milestones - **Analyst Day**: Scheduled for February 10, 2026, to discuss growth trajectory and upcoming catalysts [24] - **Clinical Data Updates**: Expected for TPN study and Rezzayo sNDA submission in early 2027 [24][35] Regulatory and Competitive Landscape - **Legislative Risks**: Potential changes in TDAPA reimbursement structure could impact future revenue [35] - **Intellectual Property**: Strong IP protection for DefendCath and Rezzayo, with exclusivity extending into the 2030s [38][39] Conclusion - **Outlook**: CorMedix is positioned as a robust, diversified specialty pharmaceutical company with a strong financial profile and significant growth potential through its product pipeline and strategic initiatives [26]